W
Wolf H. Fridman
Researcher at University of Paris
Publications - 551
Citations - 60835
Wolf H. Fridman is an academic researcher from University of Paris. The author has contributed to research in topics: Immune system & Receptor. The author has an hindex of 97, co-authored 525 publications receiving 48713 citations. Previous affiliations of Wolf H. Fridman include Queen Elizabeth Hospital Birmingham & Pasteur Institute.
Papers
More filters
Journal ArticleDOI
Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates
Wolf H. Fridman,Jérôme Galon,Franck Pagès,Eric Tartour,Catherine Sautès-Fridman,Guido Kroemer +5 more
TL;DR: Improved methods for the automation of immunohistochemistry and digitalized image analyses will pave the way to an improved understanding of the complex interplay between cancer parenchyma, stroma, and immune effectors, as well as to the routine evaluation of immune-related parameters to the clinical management of cancer patients.
Journal ArticleDOI
Heterozygous and Homozygous Factor H Deficiencies Associated with Hemolytic Uremic Syndrome or Membranoproliferative Glomerulonephritis: Report and Genetic Analysis of 16 Cases
Marie-Agnès Dragon-Durey,Véronique Frémeaux-Bacchi,Chantal Loirat,Jacques Blouin,Patrick Niaudet,Georges Deschênes,Paul Coppo,Wolf H. Fridman,Laurence Weiss +8 more
TL;DR: The variability in the clinical progression of kidney diseases associated with FH deficiencies is emphasized, and genetic analysis reveals the molecular abnormalities associated withFH deficiencies to be polymorphous.
Journal ArticleDOI
Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome
Véronique Frémeaux-Bacchi,Marie-Agnès Dragon-Durey,Jacques Blouin,C Vigneau,Dirk Kuypers,Bernard Boudailliez,Chantal Loirat,Eric Rondeau,Wolf H. Fridman +8 more
TL;DR: Two complement alternative pathway proteins, factor H (FH) and recently membrane cofactor protein (CD46; MCP) have been identified as fostering the development of atypical HUS.
Journal ArticleDOI
Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
Nicolas A. Giraldo,Nicolas A. Giraldo,Nicolas A. Giraldo,Etienne Becht,Etienne Becht,Etienne Becht,Franck Pagès,Georgios P Skliris,Virginie Verkarre,Yann Vano,Arnaud Mejean,Nicolas Saint-Aubert,Laetitia Lacroix,Laetitia Lacroix,Laetitia Lacroix,Ivo Natario,Ivo Natario,Ivo Natario,Audrey Lupo,Marco Alifano,Diane Damotte,Aurélie Cazes,Frédéric Triebel,Gordon J. Freeman,Marie-Caroline Dieu-Nosjean,Marie-Caroline Dieu-Nosjean,Marie-Caroline Dieu-Nosjean,Stéphane Oudard,Wolf H. Fridman,Catherine Sautès-Fridman +29 more
TL;DR: The expression of the immune checkpoints and the localization of DC in the tumor microenvironment modulate the clinical impact of CD8+ T cells in ccRCC.
Journal ArticleDOI
Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism.
Fabrice Benchetrit,Arnaud Ciree,Virginie Vives,Guy Warnier,Alain Gey,Catherine Sautès-Fridman,François Fossiez,Nacilla Haicheur,Wolf H. Fridman,Eric Tartour +9 more
TL;DR: IL-17, like other cytokines, appears to be a pleiotropic cytokine with possible protumor or antitumor effects on tumor development, which often depends on the immunogenicity of tumor models.